Trials / Completed
CompletedNCT02476734
FDG-PET/CT Imaging as Early Predictor of DP
A Pilot Study Using FDG-PET/CT Imaging as an Early Predictor of Disease Response in Lymphoma Subjects Receiving Redirected Autologous CART- 19 T-cell Immunotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 9 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study the investigators would like to describe FDG-PET/CT responses in patients who are receiving CART-19 immunotherapy for Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) as part of UPCC #13413. Subjects will undergo two FDG-PET/CTs. One performed within 6 weeks of CART-19 infusion and a repeat scan at about 1 month after infusion.
Detailed description
In this study the investigators described FDG-PET/CT responses in patients who were receiving CART-19 immunotherapy for Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) as part of UPCC #13413. Subjects underwent two FDG-PET/CTs. One performed within 6 weeks of CART-19 infusion and a repeat scan at about 1 month after infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | There is no intervention | Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake. |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2016-02-01
- Completion
- 2018-08-01
- First posted
- 2015-06-19
- Last updated
- 2023-07-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02476734. Inclusion in this directory is not an endorsement.